首页> 外文期刊>The Journal of Nuclear Medicine >Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and F-18-FDG PET/CT in Correlation with Clinical Pathologic Outcome
【24h】

Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and F-18-FDG PET/CT in Correlation with Clinical Pathologic Outcome

机译:肺淋巴管癌:高分辨率CT和F-18-FDG PET / CT与临床病理结果相关的诊断性能

获取原文
获取原文并翻译 | 示例
           

摘要

The rationale of this study was to investigate the performance of high-resolution CT (HRCT) versus F-18-FDG PET/CT for the diagnosis of pulmonary lymphangitic carcinomatosis (PLC). Methods: In this retrospective institution-approved study, 94 patients addressed for initial staging of lung cancer with suspicion of PLC were included. Using double-blind analysis, we assessed the presence of signs favoring PLC on HRCT (smooth or nodular septa lines, subpleural nodularity, peribronchovascular thickening, satellite nodules, lymph node enlargement, and pleural effusion). F-18-FDG PET/CT images were reviewed to qualitatively evaluate peritumoral uptake and to quantify tracer uptake in the tumoral and peritumoral areas. Histology performed on surgical specimens served as the gold standard for all patients. Results: Among 94 included patients, 73% (69/94) had histologically confirmed PLC. Peribronchovascular thickening, lymph node involvement, and increased peritumoral uptake were more often present in patients with PLC (P < 0.009). Metabolic variables, including tumor SUVmax, SUVmean, metabolic tumor volume, and total lesion glycolysis, as well as peritumoral SUVmax, SUVmean, and their respective ratios to background, were significantly higher in the PLC group than in the non-PLC group (P <= 0.0039). Sensitivity, specificity, and area under the receiver-operating-characteristic curve for peribronchovascular thickening (69%, 83%, and 0.76, respectively; 95% confidence interval [95%CI], 0.67-0.85) and increased peritumoral uptake (94%, 84%, and 0.89, respectively; 95%CI, 0.81-0.97) were similar (P = 0.054). For detecting PLC, sensitivity, specificity, and area under the receiver-operating-characteristic curve were significantly higher, at 97%, 92%, and 0.98, respectively (95%CI, 0.96-1.00), for peritumoral SUVmax and 94%, 88%, and 0.96, respectively (95%CI, 0.92-1.00), for peritumoral SUVmean (all P <= 0.025). Conclusion: Qualitative evaluation of F-18-FDG PET/CT and HRCT perform similarly for the diagnosis of PLC, with both being outperformed by F-18-FDG PET/CT quantitative parameters.
机译:本研究的基本原理是探讨高分辨率CT(HRCT)对F-18-FDG PET / CT的性能,用于诊断肺淋巴管癌(PLC)。方法:在这个回顾性制度批准的研究中,包括呼吸肺癌初始分期的94名患者,怀疑PLC。使用双盲分析,我们评估了HRCT上有利于PLC的迹象的存在(光滑或结节型隔膜线,副间结,血频血管增稠,卫星结节,淋巴结扩大和胸腔积液)。综述F-18-FDG PET / CT图像以定性地评估腹部摄取和量化肿瘤和腹部区域中的示踪吸收。对外科标本进行的组织学用作所有患者的黄金标准。结果:94名患者中,73%(69/94)有组织学证实PLC。 PLC患者更常见的血浆化血管增稠,淋巴结受累和增加的腹部摄取(P <0.009)。 PLC组中的代谢变量包括肿瘤Suvmax,Suvmax,Suvmean,代谢肿瘤肿瘤体积和总损伤糖酵解以及背景的腹膜术,Suvmean及其各自的比例显着高于非PLC组(P <) = 0.0039)。接收器的敏感性,特异性和面积分别为泛刺血管增稠(69%,83%和0.76; 95%置信区间[95%CI],0.67-0.85)和腹部摄取增加(94% 84%和0.89分别; 95%CI,0.81-0.97)类似(P = 0.054)。对于检测PLC,接收器操作特征曲线下的灵敏度,特异性和面积显着升高,分别为97%,92%和0.98,分别为95%,95%,0.96-1.00),适用于94%,分别为88%和0.96(95%CI,0.92-1.00),适用于Peritumoral Suvmean(所有P <= 0.025)。结论:对于PLC的诊断,对F-18-FDG PET / CT和HRCT的定性评估,两者都是由F-18-FDG PET / CT定量参数表现出来的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号